[EN] ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES [FR] DÉRIVÉS ISOTHIAZOLE UTILES EN TANT QU'AGONISTES DE GPR120 POUR LE TRAITEMENT DU DIABÈTE DE TYPE II
[EN] ISOTHIAZOLE DERIVATIVES AS GPR120 AGONISTS FOR THE TREATMENT OF TYPE II DIABETES<br/>[FR] DÉRIVÉS ISOTHIAZOLE UTILES EN TANT QU'AGONISTES DE GPR120 POUR LE TRAITEMENT DU DIABÈTE DE TYPE II
申请人:JANSSEN PHARMACEUTICA NV
公开号:WO2015134039A1
公开(公告)日:2015-09-11
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows: wherein R1, G, and Q are defined herein.
Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
申请人:Janssen Pharmaceutica NV
公开号:US09067898B1
公开(公告)日:2015-06-30
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) as follows:
wherein R1, G, and Q are defined herein.
Novel process for the preparation of the insulin sensitizer
申请人:——
公开号:US20040267023A1
公开(公告)日:2004-12-30
A novel process for the preparation of compounds of formula I
1
and optionally converting a compound of formula I into a pharmaceutically acceptable salt is disclosed. The compounds of formula I and the corresponding salts, e.g. the sodium salts, are pharmaceutically active substances. Processes for the creation of intermediates are also disclosed.
[EN] PROCESS FOR THE PREPARATION OF INSULIN SENSITIZER AND INTERMEDIATE COMPOUND THEREOF<br/>[FR] PROCEDE DE PREPARATION D'UN SENSIBILISATEUR A L'INSULINE ET D'UN COMPOSE INTERMEDIAIRE DE CELUI-CI
申请人:HOFFMANN LA ROCHE
公开号:WO2005000844A1
公开(公告)日:2005-01-06
The present invention is concerned with a novel process for the preparation of compounds of formula (I) and optionally converting a compound of formula (I) into a pharmaceutically acceptable salt, wherein R1 and R 2 are as defined in the description and claims. The compounds of formula (I) and the corresponding salts, e.g. the sodium salts, are pharmaceutically active substances.
GPR120 agonists for the treatment of type II diabetes
申请人:Janssen Pharmaceutica NV
公开号:US10118922B2
公开(公告)日:2018-11-06
Disclosed are compounds, compositions and methods for treating of disorders that are affected by the modulation of the GPR120 receptor. Such compounds are represented by Formula (I) and Formula (II) as follows:
wherein Y, R1, G, and Q are defined herein;
and
wherein R11, R21, R41, RB1 and G1, are defined herein.